New hope for men battling aggressive prostate cancer
NCT ID NCT04754191
Summary
This study is testing whether a drug called enfortumab vedotin, given alone or with other cancer drugs, can help control advanced prostate cancer that has spread and no longer responds to standard hormone therapies. It is for men whose cancer has progressed despite prior treatments, including chemotherapy. The main goal is to see if the treatment can shrink tumors, lower a key blood marker (PSA), or keep the disease stable for at least six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.